Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Common Equity (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Common Equity for 7 consecutive years, with $505.7 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 0.97% to $505.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $505.7 million through Dec 2025, down 0.97% year-over-year, with the annual reading at $505.7 million for FY2025, 0.97% down from the prior year.
  • Common Equity for Q4 2025 was $505.7 million at 4D Molecular Therapeutics, up from $369.0 million in the prior quarter.
  • The five-year high for Common Equity was $600.6 million in Q1 2024, with the low at $218.6 million in Q1 2023.
  • Average Common Equity over 5 years is $363.8 million, with a median of $322.1 million recorded in 2021.
  • The sharpest move saw Common Equity skyrocketed 385.07% in 2021, then plummeted 33.27% in 2025.
  • Over 5 years, Common Equity stood at $319.1 million in 2021, then fell by 27.5% to $231.3 million in 2022, then skyrocketed by 33.07% to $307.8 million in 2023, then surged by 65.87% to $510.6 million in 2024, then fell by 0.97% to $505.7 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $505.7 million, $369.0 million, and $420.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.